Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Health habits’ connection to dementia in the spotlight as new year begins
By
Lois A. Bowers
Jan 04, 2022
An update to the National Plan to Address Alzheimer’s Disease, as well as news of potential treatments and a finding that “astonished” researchers add up to promising news to start the new...
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).
Ethical considerations explored for aducanumab in Alzheimer’s disease
Nov 19, 2021
Grounds are insufficient to offer aducanumab (Aduhelm) for moderate, advanced Alzheimer’s dementia or for individuals without biomarker evidence of brain ß-amyloid, according to a position statement.
Most with Alzheimer’s disease, mild cognitive impairment would have been excluded from aducanumab...
Sep 16, 2021
Overall, 92.2, 91, and 85.5% of Medicare beneficiaries with Alzheimer’s disease-related disorders, Alzheimer’s disease, and mild cognitive impairment met at least one of the exclusion criteria.
Expert panel publishes first recommendations on appropriate use of Alzhemier’s drug Aduhelm
By
Kimberly Bonvissuto
Jul 27, 2021
A panel of experts in the Alzheimer’s field this morning published the first recommendations for the appropriate use of aducanumab (Aduhelm), the controversial new drug to treat early, mild disease.
A very troubling $56 billion question
By
John O'Connor
Jul 08, 2021
Considering some of the alternatives, I’m far from convinced that bankrupting Medicare for the sake of Aduhelm would be money well spent.
House committees to investigate new Alzheimer’s disease drug approval
Jul 01, 2021
The FDA approved aducanumab earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness.
3 FDA advisory panel members resign in wake of controversial approval of new Alzheimer’s drug
By
Kimberly Bonvissuto
Jun 11, 2021
Three members of a Food & Drug Administration advisory panel resigned this week over the agency’s controversial decision on Monday to approve a novel therapy for Alzheimer’s disease.